language English
Article 2023 · 6 atıf

Radioprotective effects of α2-adrenergic receptor agonist dexmedetomidine on X-ray irradiation-induced pancreatic islet cell damage

Mercantepe, Filiz, Tumkaya, Levent, Mercantepe, Tolga, Rakici, Sema Yilmaz, Ciftel, Serpil, Ciftel, Sedat

Özet

Comprehensive epidemiological analyses conducted in the last 30 years have revealed a link between radiation and DM. We aimed to determine the effects of dexmedetomidine pretreatment on radiation-induced pancreatic islet cell damage. Twenty-four rats were divided into three groups: group 1 (control group), group 2 (only X-ray irradiation group), and group 3 (X-ray irradiation + dexmedetomidine). We observed necrotic cells with vacuoles accompanying loss of cytoplasm in the islets of Langerhans, extensive edematous areas, and vascular congestions in group 2. In group 3, we observed a decrease in necrotic cells in the islets of Langerhans, and edematous areas and vascular congestion was also reduced. We determined a decrease in beta-cells, alpha-cells, and D-cells in the islets of Langerhans in group 2 compared to the control group. In group 3, beta-cells, alpha-cells, and D-cells were elevated compared to group 2. Ionizing radiation may induce DM. Dexmedetomidine appears to exert a radioprotective effect.

Anahtar Kelimeler
Beta-cell Dexmedetomidine Diabetes mellitus Pancreas X-ray irradiation LONG-TERM SURVIVORS DIABETES-MELLITUS CHILDHOOD-CANCER ABDOMINAL RADIATION RISK ENDOCRINE RADIOTHERAPY THERAPY
WoS Kategorileri
Pharmacology & Pharmacy
Sürdürülebilir Kalkınma Amaçları
Künye
Dergi
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Yıl
2023
Cilt
396
Sayı
8
Sayfa
1827-1836
ISSN
0028-1298
eISSN
1432-1912
DOI
10.1007/s00210-023-02454-0
WoS UID
WOS:000943971800004
Yayını aç (DOI)